A new guideline is coming! The AGA Clinical Practice Guideline on Intestinal Microbiota Transplantation for Gastrointestinal Diseases will be published in early 2024.
Intestinal microbiota transplant (IMT), historically named fecal microbiota transplant, is a treatment for gut dysbiosis. AGA offers seven recommendations for the use of IMT in patients with recurrent C. difficile infections, severe to fulminant C. difficile infections, inflammatory bowel diseases including pouchitis, and irritable bowel syndrome.
As part of our guideline development process, we invite you to review this new guideline and share feedback during the public comment period.
Guideline documents for review
About the public comment period
AGA develops clinical practice guidelines using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which provides a common, sensible and transparent approach to grading the quality of evidence and strength of recommendations, and uses the best practices outlined by the Institute of Medicine.
The public comment period is an integral part of AGA’s guideline development process. It allows AGA members and key stakeholders to review and comment on upcoming guidelines and their accompanying technical reviews.
Once an AGA guideline panel releases the drafts for public comment, identified stakeholders are alerted and submit their comments through an online survey. After the period ends, the guideline panel reviews and responds to the comments within two weeks. Revisions to the draft documents are at the discretion of the panel, but all comments will be considered and responses internally documented.
To see previously published guidelines, visit AGA’s clinical guidance library.